Total Funding
49
38
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
152825
Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms.
- Alfredo Zurlo: Chief Medical Officer
- Jan Stenvang: Co-founder and Chief Scientific OfficerPast Role: Scandion Oncology, Co-Founder & Chief Technology Officer
About the Company
Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is their mission. Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy. Although many
cancer patients initially benefit from chemotherapy, a large proportion develop resistance to chemotherapy drugs. Few of these patients survive.
